Novel Europium Based Time-Resolve Fluorophore with Exceptional Intensity and Stab

新型铕基时间分辨荧光团，具有卓越的强度和稳定性

• 批准号: 8000276
• 负责人: Darren J Magda
• 金额: $ 18.94万
• 依托单位: LUMIPHORE, INC.
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-20 至 2011-09-19
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8000276
• 关键词: Arts; Benchmarking; Binding; Biological; Biological Assay; Biological Sciences; Biomedical Research; Biotin; Buffers; Businesses; California; Characteristics; Chelating Agents; Chemistry; Clinical; Code; Color; Complex; Computer Systems Development; Coupled; DNA Sequence; Detection; Development; Diagnosis; Diagnostic; Divalent Cations; Dyes; Elements; Energy Transfer; Ensure; Environment; Equipment; Europium; Exhibits; Extinction (Psychology); Family; Flow Cytometry; Fluorescence; Fluorescence Microscopy; Fluorescence Resonance Energy Transfer; Fluorescent Dyes; France; Gamma globulin; Generations; Genomics; Germany; Healthcare; Image; Immune; Immunoassay; Industry; International; Ions; Kinetics; Label; Lanthanoid Series Elements; Lasers; Lead; Licensing; Life; Ligands; Light; Link; Marketing; Modeling; Nature; Noise; Patient Care; Phase; Play; Property; Proteins; Public Health; Reading; Reagent; Reporter; Research; Research Personnel; Research Proposals; Role; Route; Sampling; Screening procedure; Signal Transduction; Solutions; Source; Speed; Streptavidin; System; Technology; Terbium; Time; Universities; Utah; Vertebral column; absorption; aqueous; arm; base; commercialization; cost; cyanine dye 5; diagnostic accuracy; drug discovery; fluorophore; high throughput screening; improved; innovation; instrument; luminescence; macromolecule; next generation; novel; novel diagnostics; physical property; practical application; prevent; protein protein interaction; public health relevance; quantum; research and development; sound; usability

DESCRIPTION (provided by applicant): Due to their favorable photophysical and spectral properties, complexes of lanthanide ions (particularly Terbium and Europium) offer significant advantages over organic fluorescent dyes. Compared with traditional organic fluorescent materials, the lanthanide coordination compounds have the following properties - long life-time, a large Stokes shift, and sharp fluorescent peak profiles. Due to these attractive properties, time-resolved reagents based on lanthanide fluorescence have been created. However, existing lanthanide products have not been fully successful in producing products with sufficient stability and brightness to compete with conventional organic fluorophores. Under this Phase I SBIR, Lumiphore will develop a Europium (Eu) fluorescent reporter based on the novel 1,2-HOPO sensitizing unit. The proposed reporter (Lumi4-Eu) will have exceptional photophysical and stability characteristics that will set a new benchmark for Eu reporters in a wide range of drug discovery, diagnostic, rapid sequencing and array applications. This research will result in a fluorescence reagent with exceptional stability, usability, and fluorescent properties that will expand the capabilities of time resolved fluorescent diagnostics by offering the second color of a duplex set of compatible, but complementary lanthanide reporters (the other being Lumiphore's terbium-based fluorescence reporter - Lumi4-Tb). Combining Lumi4- Eu and Lumi4-Tb will enable a new generation of time resolved fluorescence or time resolved Fvrster resonant energy transfer (TR-FRET) based multiplex applications. Lumiphore will use this technology to develop a rapid, multiplexed immunoassay diagnostic platform. This platform holds the promise of exquisite sensitivities, speed, and versatility for the increasing demands of 21st century healthcare. PUBLIC HEALTH RELEVANCE: The proposed research when combines with Lumiphore's existing terbium-based fluorescence reporter (Lumi4-Tb) will impact public health by enabling highly multiplexed diagnostic assay formats that combine fast turnaround times and high assay throughput efficiency. These assays will be used in high throughput screening (HTS) drug discovery, genomic screening, rapid DNA sequencing, clinical diagnostics and fluorescence microscopy applications for both basic and applied biomedical research.

描述（由申请人提供）：由于其有利的光物理和光谱特性，兰烷基离子（尤其是Terbium和Europium）的复合物比有机荧光染料具有显着优势。与传统的有机荧光材料相比，灯笼的配位化合物具有以下特性 - 长寿，大的Stokes Shift和尖锐的荧光峰轮廓。由于这些有吸引力的特性，已经创建了基于灯笼荧光的时间分辨试剂。但是，现有的灯笼产品在生产具有足够稳定性和亮度的产品方面尚未完全成功，以与传统的有机荧光团竞争。在此I阶段I SBIR下，Lumiphore将基于新型的1,2-Hopo敏化单元来开发Europium（EU）荧光记者。拟议的记者（Lumi4-eu）将具有出色的光体物理和稳定性特征，该特征将为欧盟记者提供新的基准，以在广泛的药物发现，诊断，快速测序和阵列应用中为欧盟记者树立。这项研究将导致具有出色稳定性，可用性和荧光性能的荧光试剂，通过提供一套复合兼容但互补的灯笼式灯lumiphore的lumiphore terbium基于Terbium的荧光epororter-lumi4-tb）来扩大时间解决荧光诊断能力的能力。结合Lumi4-EU和Lumi4-TB将使新一代的时间分辨荧光或时间分析的FVRSTER共振能量转移（TR-FRET）的多重应用。 Lumiphore将使用这项技术开发快速，多重的免疫测定诊断平台。该平台对21世纪医疗保健需求不断增长的敏感性，速度和多功能性具有强大的敏感性，速度和多功能性的希望。 公共卫生相关性：拟议的研究与Lumiphore现有的基于Terbium的荧光报告基因（Lumi4-TB）结合使用，将通过启用高度多重的诊断测定格式来影响公共卫生，以结合快速周转时间和高分测定的吞吐量效率。这些测定将用于高通量筛查（HTS）药物发现，基因组筛查，快速DNA测序，临床诊断和荧光显微镜应用，用于基本和应用生物医学研究。